Lee M. Nadler, MD

Dana Farber Cancer Institute
Harvard Medical School
Boston, MA
(866) 408-DFCI (3324)
http://www.dana-farber.org

Dr. Nadler received his MD from Harvard Medical School in 1973. After residency training at Columbia-Presbyterian Medical Center, and training at the National Cancer Institute in tumor immunology, he completed a medical oncology fellowship at DFCI, where he joined the staff in 1980. During his tenure at DFCI, he has served as chief and chair of several departments.

Appleman LJ, van Puijenbroek AA, Shu KM, Nadler LM, Boussiotis VA. CD28 costimulation mediates downregulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells. J Immunol 2002;168(6):2729-36.

Nadler LM, Schultze JL. From genomics to cancer vaccines: patient-tailored or universal vaccines? Curr Opin Mol Ther 2002;4(6):572-6.

Tzachanis D, Berezovskaya A, Nadler LM, Boussiotis VA. Blockade of B7/CD28 in mixed lymphocyte reaction cultures results in the generation of alternatively activated macrophages, which suppress T cell responses. Blood 2002;99(4):1465-73.

von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, Hirano N, Anderson KS, Butler MO, Xia Z, Zeng WY, Wucherpfennig KW, Nadler LM, Schultze JL. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 2002;99(9):3319-25.

Tzachanis D, Freeman GJ, Hirano N, van Puijenbroek AA, Delfs MW, Berezovskaya A, Nadler LM, Boussiotis VA. Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat Immunol 2001;2(12):1174-82.

Vonderheide RH, Anderson KS, Hahn WC, Butler MO, Schultze JL, Nadler LM. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res 2001;7(11):3343-8.

Vonderheide RH, Butler MO, Liu JF, Battle TE, Hirano N, Gribben JG, Frank DA, Schultze JL, Nadler LM. CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/CD86 expression or T cell alloreactivity. Int J Oncol 2001;19(4):791-8.

Vonderheide RH, Schultze JL, Anderson KS, Maecker B, Butler MO, Xia Z, Kuroda MJ, von Bergwelt-Baildon MS, Bedor MM, Hoar KM, Schnipper DR, Brooks MW, Letvin NL, Stephans KF, Wucherpfennig KW, Hahn WC, Nadler LM. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res 2001;61(23):8366-70.

Boussiotis VA, Freeman GJ, Taylor PA, Berezovskaya A, Grass I, Blazar BR, Nadler LM. p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat Med 2000;6(3):290-7.